Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on on healthcare or medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. For up-to-date information on other healthcare topics, please consult the relevant reliable sources or an healthcare expert, such as a physician etc.
 BACK TO LIST

European Patient Summary

Patient
Name: Thibault, Louis
DOB: 24-JUL-1960 (Age: 65)
Gender: male
ID: 1129-809340-9 (ECI)
Author
Dr. Ping, Hel
Patient summary Document
European Patient Summary
Report Date: 27-JAN-2025

Problem list

Condition Onset Date Status
Ischemic heart disease 30-Dec-2019 active
Fibromyalgia 05-Feb-2014 active
Osteoarthritis of knee 01-Sep-1997 active
Essential hypertension 25-Aug-1997 active
Sepsis 08-Nov-1995 active
Prediabetes 21-Nov-1977 active
Anemia 21-Nov-1977 active

Medication list

No known medications

Immunizations list

Vaccine Date
Influenza virus antigen only vaccine product 26-Jan-2025
Streptococcus pneumoniae Danish serotype 1 09-Jan-2022
SARS-CoV-2 mRNA vaccine 11-Apr-2021
Streptococcus pneumoniae Danish serotype 1 03-Jan-2021
Clostridium tetani toxoid antigen adsorbed only vaccine product 11-Dec-2016

Allergies and Intolerances

Allergy/Intolerance Onset Date Status Type Reaction
Vaccine product containing only Clostridium tetani toxoid antigen adsorbed ? active ?

Care Plan

Active Planned Care / Goals Start Date Reason
Musculoskeletal care 01-Sep-1997 Osteoarthritis of knee
  • Reduce knee pain severity to a tolerable level to improve mobility and quality of life.
  • Increase ability to walk and perform daily activities without significant limitation from knee osteoarthritis.
  • Decrease swelling and inflammation in the affected knee to minimize discomfort and prevent further joint damage.
Lifestyle education regarding hypertension 25-Aug-1997 Essential hypertension (disorder)
  • Maintain blood pressure below 130/80 mmHg through lifestyle modifications.
  • Achieve a 5% reduction in body weight to assist in blood pressure management.
  • Engage in at least 150 minutes of moderate-intensity aerobic physical activity per week.
  • Limit sodium intake to less than 2.3 grams per day to support blood pressure control.
Diabetes self management plan 21-Nov-1977 Prediabetes
  • Patient will implement and maintain lifestyle modifications to reduce risk of progression to diabetes, including dietary changes, increased physical activity, and regular blood glucose monitoring.
  • Patient will achieve a weight loss of at least 5% of baseline body weight through dietary and physical activity interventions.
  • Patient will maintain blood pressure below 130/80 mmHg to reduce cardiovascular risk.
Immunization Recommendation Due Date Reason
Vaccine product containing only Influenza virus antigen (medicinal product) 01-Oct-2025 Annual seasonal influenza vaccination

Vital Signs

Vital Signs 2025-01-26 2024-01-21
Body Height 164.3 cm 164.3 cm
Pain severity - 0-10 verbal numeric rating [Score] - Reported 3 {score} 2 {score}
Body Weight 69.5 kg 69.5 kg
Body mass index (BMI) [Ratio] 25.8 kg/m2 25.8 kg/m2
Diastolic Blood Pressure 76 mm[Hg] 76 mm[Hg]
Systolic Blood Pressure 115 mm[Hg] 109 mm[Hg]
Heart rate 73 /min 98 /min
Respiratory rate 13 /min 15 /min

Relevant diagnostic tests/laboratory data

Recent Lab Observations 27-JAN-2025 Reference Range Unit
Hemoglobin A1c/Hemoglobin.total in Blood 6.3 4.5 - 6.4 %
Glucose [Mass/volume] in Blood 93.9 70 - 99 mg/dL
Urea nitrogen [Mass/volume] in Blood 7.1 7 - 20 mg/dL
Creatinine [Mass/volume] in Blood 0.8 0.6 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 8.5 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Blood 142.0 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 5.2 H 3.5 - 5 mmol/L
Chloride [Moles/volume] in Blood 110.0 H 98 - 108 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 24.8 22 - 32 mmol/L
Cholesterol [Mass/volume] in Serum or Plasma 199.0 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 135.1 0 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 139.5 H 0 - 130 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 32.4 L 40 - 60 mg/dL

Device Use

Device Date (since)
Manual wheelchair (physical object) 31-Aug-1997
Wheelchair accessory (physical object) 31-Aug-1997
Blood glucose meter (physical object) 20-Nov-1977